Company: KROS
Filing Date: 2025-08-06
Form Type: 8-K
Source: 0001664710-25-000071
Chunk: 4

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 8-K
Item: Item 5.02
Chunk 4
---
b) a lump sum payment equal to

100% of her target bonus for the year of termination; (c) payment of COBRA premiums for up to 12 months; and (d) acceleration of all of her unvested and outstanding equity time-based vesting awards.

There are no arrangements or understandings between Ms. Cho and any other person pursuant to which the Cho Employment Agreement was entered into. Other than with respect to the Cho Employment Agreement, there are no transactions to which the Company is a party and in which Ms. Cho has a material interest that are required to be disclosed under Item 404(a) of Regulation S-K. Ms. Cho has no family relations with any directors or executive officers of the Company.

The foregoing description of the Cho Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Cho Employment Agreement, which is filed as Exhibit 10.3 to this Current Report on Form 8-K and incorporated herein by reference.

In connection with the Cho Employment Agreement, the Company will enter into its standard form of indemnification agreement with Ms. Cho. The indemnification agreement will provide, among other things, that the Company will indemnify Ms. Cho for certain expenses, including damages, judgments, fines, penalties, settlements and costs and attorneys’ fees and disbursements, incurred in any claim, action or proceeding arising in her capacity as an executive officer or in connection with service at the Company’s request for another corporation or entity.

Transition of Jasbir Seehra from Chief Executive Officer and Chair of the Board of Directors to President, Chief Executive Officer and Director

On August 6, 2025, the Board of Directors (the “ Board”) of the Company appointed Jasbir Seehra, Chief Executive Officer of the Company, to the additional position of President of the Company, effective as of August 18, 2025. Additionally, Dr. Seehra, who currently serves as Chair of the Board, will cease serving in this role, effective as of August 18, 2025, but will continue to serve as a member of the Board.

Appointment of Jean-Jacques Bienaimé as Chair of the Board

On August 6, 2025, the Board appointed Jean-Jacques Bienaimé as Chair of the Board, effective as of August 18, 2025. In connection with Mr. Bienaimé’s appointment as Chair of the Board, he will be entitled to receive a